← 產業報告目錄

Interventional Cardiology Devices Market by Type [Stents (Drug-eluting Stent, Bare Metal Stent), Catheters (Angiography, Guiding, IVUS/OCT Catheters), Balloons, Plaque Modification Devices, Hemodynamic Flow Alteration], End User - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-02-03頁數 469報告編號 MD3456

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global interventional cardiology devices market is projected to reach USD 42.39 billion by 2031, from USD 31.12 billion in 2026, growing at a CAGR of 6.4% during the forecast period. The worldwide interventional cardiology devices market is growing mainly because of factors such as a higher incidence of cardiovascular diseases, a preference for less invasive procedures, and an aging global population. In addition, innovations in medical technology, such as drug-eluting stents, bioresorbable scaffolds, and enhanced imaging with catheter-based techniques, are making procedures safer and more successful. Furthermore, the spread of better healthcare facilities in developing countries, the introduction of reimbursement policies that encourage treatment in developed regions, and higher consumer awareness of heart disease detection and treatment are also contributing to market growth. “Based on the angioplasty balloon type, the old/normal balloons segment is expected to grow by the highest CAGR in the interventional cardiology devices market.” The old or normal (plain) angioplasty balloons segment of the angioplasty balloons market is growing due to low cost, general acceptance in clinical practice, and high usage in routine and first-line percutaneous coronary interventions, especially in developing and cost-sensitive healthcare settings. They are frequently used to prepare the lesion for stent placement and in uncomplicated coronary and peripheral procedures, which helps maintain demand. Moreover, their established safety record, user-friendliness, and the wide range of available sizes make them the preferred option in high-volume hospitals, thereby contributing to the continuous growth of the market, even though there have been developments in the technologies for specialty balloons. “The embolic protection devices segment in the hemodynamic flow alteration devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market.” Cardiovascular and neurovascular interventions, especially transcatheter aortic valve replacement (TAVR), carotid artery stenting, and peripheral vascular procedures, are the main drivers of increased sales of embolic protection devices in the hemodynamic flow alteration device market. These devices, which prevent strokes and distal ischemia that may occur as a side effect of the procedure, have led to more patients being treated and better clinical outcomes. Market growth is supported by technological advancements that yield better filters, more efficient capture, and easier deliverability, as well as by positive clinical evidence and the rising popularity of minimally invasive procedures among the elderly. “The guidewires segment in the other devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market.” Growth in the interventional cardiology devices market's guidewires segment is primarily driven by the rising incidence of surgical interventions involving percutaneous coronary angioplasty, a direct result of the global rise in cardiovascular diseases. Guidewires are among the most essential items for interventional procedures, creating steady demand in hospitals and catheterization labs. Emerging technologies, such as improved torque control, greater flexibility, hydrophilic coatings, and enhanced lesion-crossing ability, have expanded their use in complex and chronic total occlusion procedures. In addition, the growing preference for minimally invasive treatments, expanding healthcare infrastructure in developing countries, and the large number of procedures performed in both diagnostic and therapeutic interventions continue to support the market growth. “Based on the end user, the hospital segment is expected to grow by the highest CAGR in the interventional cardiology devices market. Most interventional cardiology procedures, such as angioplasties, stent placements, and structural heart interventions, are performed in hospitals because they offer specialized facilities and sophisticated imaging technologies that support high-quality patient care. Hospitals are well-equipped for both simple and complex procedures. These settings enable cardiologists to apply the latest technologies, including drug-eluting stents, rotational atherectomy, and intravascular ultrasound, to ensure utmost precision and safety for patients. “The Asia Pacific is expected to grow with the highest CAGR in the interventional cardiology devices market during the forecast period.” The rise in cardiovascular diseases and the growing number of catheter-based heart surgeries performed in hospital settings have been the main drivers of growth in the interventional cardiology devices market. Hospitals are major end users, where complex and high-risk interventions are carried out because of their advanced infrastructure, the presence of skilled interventional cardiologists, and access to hybrid operating rooms and cath labs. The increasing use of minimally invasive techniques, favorable reimbursement for inpatient and outpatient cardiac interventions, and hospitals' ongoing investment in advanced interventional technologies also support their dominance and contribute to market growth. The breakup of the profile of primary participants in the interventional cardiology devices market: • By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20% • By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%. • By Region: North America - 40%, Europe – 30%, APAC –20%, Latin America – 5%,Middle East & Africa–5% Key players in the interventional cardiology devices market Some of the prominent players operating in the interventional cardiology devices market include Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Penumbra, Inc. (US), Cook (US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd (Singapore), BIOTRONIK SE & Co. KG (Germany), AMG International (Germany), ENDOCOR GmbH (Germany), InSitu Technologies, Inc. (US), Meril Life Sciences (India), Alvimedica (Istanbul), Cardionovum GmBH (Germany), Medinol Ltd (Turkey), Wellinq (Netherlands), Balton SP (Poland), Translumina (India). Research Coverage: The report analyzes the interventional cardiology devices market and aims to estimate the market size and future growth potential across segments such as angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices, and end users. The report also includes a product portfolio matrix of the interventional cardiology technologies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies. Reasons to Buy the Report The report will provide market leaders and new entrants in this market with the closest available estimates of revenue for the overall interventional cardiology devices market and its subsegments. It will help stakeholders understand the competitive landscape and gain insights to position their businesses more effectively and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides information on key market drivers, restraints, challenges, and opportunities. This report provides insights into the following pointers: • Analysis of key drivers (Growing prevalence of cardiovascular diseases, Technological Advancements in interventional cardiology procedures, Increased prevalence of diabetes), restraints (Availability of alternative treatments, Recall of Products by Industry Participants to Limit the Uptake of Interventional Cardiology Equipment), opportunities (Growing Coronary Stent Demand in Developing Countries, Growing Product Launches by Leading Players in Developing Countries) challenges (Stringent regulatory requirements delaying the approval of cardiac devices) • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global interventional cardiology devices market. • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global interventional cardiology devices market • Market Development: Comprehensive information on the lucrative emerging markets by angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices, and end users. • Market Diversification: Exhaustive information about new products and services or product and service enhancements, growing geographies, recent developments, and investments in the global interventional cardiology devices market. • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global interventional cardiology devices market.
目錄 Table of Contents
1 INTRODUCTION 36 1.1 STUDY OBJECTIVES 36 1.2 MARKET DEFINITION 36 1.3 STUDY SCOPE 36 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 37 1.3.2 INCLUSIONS & EXCLUSIONS 38 1.3.3 YEARS CONSIDERED 38 1.3.4 CURRENCY CONSIDERED 38 1.4 MARKET STAKEHOLDERS 39 1.5 LIMITATIONS 39 1.6 SUMMARY OF CHANGES 39 2 EXECUTIVE SUMMARY 41 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 41 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 42 2.3 DISRUPTIVE TRENDS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET 43 2.4 HIGH-GROWTH SEGMENTS 44 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 45 3 PREMIUM INSIGHTS 47 3.1 INTERVENTIONAL CARDIOLOGY DEVICES MARKET OVERVIEW 47 3.2 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER AND COUNTRY (2025) 48 3.3 INTERVENTIONAL CARDIOLOGY MARKET: REGION (2026−2031) 49 4 MARKET OVERVIEW 50 4.1 INTRODUCTION 50 4.2 MARKET DYNAMICS 50 4.2.1 DRIVERS 51 4.2.1.1 Rising global burden of cardiovascular diseases 51 4.2.1.2 Technological advancements and innovations in interventional cardiology devices 52 4.2.1.3 Increasing prevalence of diabetes 52 4.2.1.4 Growing adoption of minimally invasive cardiac procedures 53 4.2.1.5 Reimbursement coverage for interventional cardiology procedures 54 4.2.2 RESTRAINTS 54 4.2.2.1 Risk of procedure-related complications 54 4.2.2.2 Product recalls and safety concerns 55   4.2.3 OPPORTUNITIES 56 4.2.3.1 High growth potential in emerging markets 56 4.2.3.2 Increasing adoption of structural heart therapies 56 4.2.4 CHALLENGES 57 4.2.4.1 Stringent regulatory requirements for product approvals 57 4.3 UNMET NEEDS & WHITE SPACES 58 4.3.1 UNMET NEEDS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET 58 4.3.2 WHITE SPACE OPPORTUNITIES 59 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 60 4.4.1 INTERCONNECTED MARKETS 60 4.4.2 CROSS-SECTOR OPPORTUNITIES 61 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 61 4.5.1 STRATEGIC MOVES IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET 61 5 INDUSTRY TRENDS 62 5.1 PORTER’S FIVE FORCES ANALYSIS 62 5.1.1 THREAT OF NEW ENTRANTS 63 5.1.2 THREAT OF SUBSTITUTES 64 5.1.3 BARGAINING POWER OF SUPPLIERS 64 5.1.4 BARGAINING POWER OF BUYERS 64 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 65 5.2 MACROECONOMIC INDICATORS 65 5.2.1 INTRODUCTION 65 5.2.2 GDP TRENDS & FORECAST 65 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 66 5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 66 5.3 SUPPLY CHAIN ANALYSIS 67 5.4 VALUE CHAIN ANALYSIS 69 5.5 ECOSYSTEM ANALYSIS 70 5.5.1 MANUFACTURERS 71 5.5.2 END USERS 71 5.5.3 REGULATORY BODIES 72 5.6 PRICING ANALYSIS 73 5.6.1 AVERAGE SELLING PRICE TREND OF INTERVENTIONAL CARDIOLOGY DEVICES, BY TYPE, 2023–2025 73 5.6.2 AVERAGE SELLING PRICE TREND OF INTERVENTIONAL CARDIOLOGY DEVICES, BY REGION, 2023–2025 76 5.7 TRADE ANALYSIS 77 5.7.1 IMPORT DATA (HS CODE 9018) 78 5.7.2 EXPORT DATA FOR (HS CODE 9018) 78 5.7.3 IMPORT DATA (HS CODE 9021) 79 5.7.4 EXPORT DATA FOR (HS CODE 9021) 80   5.8 REIMBURSEMENT SCENARIO 80 5.9 KEY CONFERENCES & EVENTS, 2026–2027 82 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 82 5.11 INVESTMENT & FUNDING SCENARIO 83 5.12 CASE STUDY ANALYSIS 84 5.13 IMPACT OF 2025 US TARIFFS ON INTERVENTIONAL CARDIOLOGY DEVICES MARKET 85 5.13.1 INTRODUCTION 85 5.13.2 KEY TARIFF RATES 86 5.13.3 PRICE IMPACT ANALYSIS 88 5.13.4 IMPACT ON COUNTRY/REGION 88 5.13.5 IMPACT ON END-USE SEGMENTS 89 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 91 6.1 TECHNOLOGY ANALYSIS 91 6.1.1 KEY EMERGING TECHNOLOGIES 91 6.1.1.1 Advanced imaging & AI-assisted guidance systems 91 6.1.1.2 Robotics & precision navigation technologies 91 6.1.2 COMPLEMENTARY TECHNOLOGIES 91 6.1.2.1 Advanced intravascular imaging modalities 91 6.1.2.2 Intravascular imaging (IVUS/OCT) 92 6.1.3 ADJACENT TECHNOLOGIES 92 6.1.3.1 Wearables & remote monitoring integrated with interventional care 92 6.2 TECHNOLOGY/PRODUCT ROADMAP 92 6.2.1 NEAR TERM (2025–2027) 92 6.2.2 MID TERM (2028–2030) 93 6.2.3 LONG TERM (2030+) 93 6.3 PATENT ANALYSIS 93 6.3.1 JURISDICTION & TOP APPLICANT ANALYSIS 93 6.4 FUTURE APPLICATIONS 98 6.4.1 AI-ENABLED & DATA-DRIVEN PROCEDURE OPTIMIZATION 98 6.4.2 PERSONALIZED CARDIOVASCULAR INTERVENTIONS 98 6.4.3 CONNECTED CARDIOVASCULAR WORKFLOWS & DIGITAL INTEGRATION 98 6.5 IMPACT OF AI/GEN AI ON INTERVENTIONAL CARDIOLOGY DEVICES 98 6.5.1 INTRODUCTION 98 6.5.2 MARKET POTENTIAL OF AI IN INTERVENTIONAL CARDIOLOGY DEVICES 99 6.5.3 AI USE CASES 99 6.5.4 KEY COMPANIES IMPLEMENTING AI 100   7 SUSTAINABILITY & REGULATORY LANDSCAPE 102 7.1 REGULATORY LANDSCAPE 102 7.1.1 REGULATORY FRAMEWORK 102 7.1.1.1 North America 102 7.1.1.2 Europe 102 7.1.1.3 Asia Pacific 102 7.1.1.4 Latin America 103 7.1.1.5 Middle East & Africa 103 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 7.1.3 INDUSTRY STANDARDS 106 7.2 SUSTAINABILITY INITIATIVES 107 7.2.1 REDUCING SINGLE-USE MEDICAL DEVICE WASTE 107 7.2.2 USE OF LOWER-IMPACT MATERIALS AND PACKAGING 107 7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 107 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 109 8.1 KEY STAKEHOLDERS & BUYING CRITERIA 109 8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS 109 8.1.2 BUYING CRITERIA 110 8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 111 8.2.1 DECISION-MAKING PROCESS 111 8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 112 8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 112 8.2.4 MARKET PROFITABILITY 113 9 ANGIOPLASTY STENTS MARKET, BY TYPE 115 9.1 INTRODUCTION 116 9.1.1 DRUG-ELUTING STENTS 118 9.1.1.1 Superior clinical outcomes and ongoing product innovations to support market growth 118 9.1.1.2 Global volume analysis of drug-eluting stents, 2024–2031 (Thousand units) 120 9.1.2 BARE-METAL STENTS 120 9.1.2.1 Cost advantages and continued adoption in resource-constrained healthcare settings to support demand 120 9.1.2.2 Global volume analysis of bare-metal stents, 2024–2031 (Thousand units) 122 9.1.3 BIOABSORBABLE STENTS 122 9.1.3.1 Advancements in resorbable scaffold technologies to boost segmental growth 122 9.1.3.2 Global volume analysis of bioabsorbable stents, 2024–2031 (Thousand units) 124 10 STRUCTURAL HEART DEVICES MARKET, BY TYPE 125 10.1 INTRODUCTION 126 10.1.1 AORTIC VALVE THERAPY DEVICES 128 10.1.1.1 Rising burden of aortic stenosis and expanding adoption of TAVI procedures to fuel growth 128 10.1.1.2 Global volume analysis of aortic valve therapy devices, 2024–2031 (Thousand units) 130 10.1.2 OTHER THERAPY DEVICES 130 10.1.2.1 Global volume analysis of other therapy devices, 2024–2031 (Thousand units) 132 11 CATHETERS MARKET, BY TYPE 133 11.1 INTRODUCTION 134 11.1.1 ANGIOGRAPHY CATHETERS 136 11.1.1.1 Growing cardiovascular disease burden and advancements in catheter technologies to support market growth 136 11.1.1.2 Global volume analysis of angiography catheters market, 2024–2031 (Thousand units) 138 11.1.2 GUIDING CATHETERS 138 11.1.2.1 Growing adoption of complex coronary interventions to drive market growth 138 11.1.2.2 Global volume analysis of guiding catheters market, 2024–2031 (Thousand units) 140 11.1.3 IVUS/OCT CATHETERS 140 11.1.3.1 Increasing adoption of intravascular imaging technologies to drive demand 140 11.1.3.2 Global volume analysis of IVUS/OCT catheters market, 2024–2031 (Thousand units) 142 12 ANGIOPLASTY BALLOONS MARKET, BY TYPE 143 12.1 INTRODUCTION 144 12.1.1 OLD/NORMAL BALLOONS 146 12.1.1.1 Low treatment costs associated with old/normal balloons to drive growth 146 12.1.1.2 Global volume analysis of old/normal balloons market, 2024–2031 (Thousand units) 148 12.1.2 DRUG-ELUTING BALLOONS 148 12.1.2.1 Increasing regulatory approvals and expanding clinical adoption to contribute to market growth 148 12.1.2.2 Global volume analysis of drug eluting balloons market, 2024–2031 (Thousand units) 150 12.1.3 CUTTING/SCORING BALLOONS 150 12.1.3.1 Increasing use in complex and calcified lesion treatment to support segmental growth 150 12.1.3.2 Global volume analysis of cutting/scoring balloons market, 2024–2031 (Thousand units) 152 13 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE 153 13.1 INTRODUCTION 154 13.1.1 THROMBECTOMY DEVICES 156 13.1.1.1 Ability to remove blood clots in STEMI and NSTEMI patients to propel market 156 13.1.1.2 Global volume analysis of thrombectomy devices market, 2024–2031 (Thousand units) 158 13.1.2 ATHERECTOMY DEVICES 158 13.1.2.1 Growing burden of calcified coronary lesions to drive market growth 158 13.1.2.2 Global volume analysis of atherectomy devices market, 2024–2031 (thousand units) 160 14 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE 161 14.1 INTRODUCTION 162 14.1.1 EMBOLIC PROTECTION DEVICES 164 14.1.1.1 Expanding use of high-risk cardiovascular interventions to propel market growth 164 14.1.1.2 Global volume analysis of embolic protection devices market, 2024–2031 (Thousand units) 166 14.1.2 CHRONIC TOTAL OCCLUSION DEVICES 166 14.1.2.1 Rising complexity of coronary lesions to fuel market growth 166 14.1.2.2 Global volume analysis of chronic total occlusion devices market, 2024–2031 (Thousand units) 168 15 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE 169 15.1 INTRODUCTION 170 15.1.1 GUIDEWIRES 172 15.1.1.1 Increasing adoption in complex coronary interventions to support market growth 172 15.1.1.2 Global volume analysis of guidewires market, 2024–2031 (Thousand units) 174 15.1.2 VASCULAR CLOSURE DEVICES 174 15.1.2.1 Increasing focus on faster hemostasis and reduced access-site complications to aid market growth 174 15.1.2.2 Global volume analysis of vascular closure devices market, 2024–2031 (Thousand units) 177 15.1.3 INTRODUCER SHEATHS 177 15.1.3.1 Increasing demand for safe and reliable vascular access to support market growth 177 15.1.3.2 Global volume analysis of introducer sheaths market, 2024–2031 (Thousand units) 179 15.1.4 BALLOON INFLATION DEVICES 179 15.1.4.1 Rising adoption of balloon-based interventions in minimally invasive procedures to boost market growth 179 15.1.4.2 Global volume analysis of balloon inflation devices market, 2024–2031 (Thousand units) 181 15.1.5 HEMOSTASIS HEART VALVES 181 15.1.5.1 Increasing focus on procedural precision and controlled hemostasis to support market growth 181 15.1.5.2 Global volume analysis of hemostasis heart valves market, 2024–2031 (Thousand units) 183 16 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER 184 16.1 INTRODUCTION 185 16.2 HOSPITALS 185 16.2.1 AVAILABILITY OF ADVANCED INFRASTRUCTURE AND SPECIALIZED EQUIPMENT TO DRIVE MARKET 185 16.3 AMBULATORY SURGERY CENTERS 189 16.3.1 SHIFT TOWARD COST-EFFICIENT AND OUTPATIENT-BASED CARE MODELS TO SUPPORT MARKET GROWTH 189 16.4 CARDIAC CARE CENTERS 191 16.4.1 GROWING IMPORTANCE OF CARDIAC CARE CENTERS IN DELIVERING SPECIALIZED CARDIOVASCULAR INTERVENTIONS TO FUEL GROWTH 191 16.5 OTHER END USERS 192 17 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION 194 17.1 INTRODUCTION 195 17.2 NORTH AMERICA 195 17.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 196 17.2.2 NORTH AMERICA: VOLUME ANALYSIS OF INTERVENTIONAL CARDIOLOGY DEVICES, BY TYPE, 2024–2031 (THOUSAND UNITS) 198 17.2.3 US 202 17.2.3.1 Favorable reimbursement coverage and growing cardiovascular disease burden to support market growth 202 17.2.4 CANADA 207 17.2.4.1 Rising cardiovascular disease burden and advancements in cardiac care to drive market growth 207 17.3 EUROPE 211 17.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 211 17.3.2 EUROPE: VOLUME ANALYSIS OF INTERVENTIONAL CARDIOLOGY DEVICES, BY TYPE, 2024–2031 (THOUSAND UNITS) 212 17.3.3 GERMANY 217 17.3.3.1 Key hub for advanced interventional cardiology technologies to boost market 217 17.3.4 FRANCE 221 17.3.4.1 Government support for cardiovascular care and technological innovation to drive market growth in France 221 17.3.5 UK 225 17.3.5.1 Increasing adoption of advanced and personalized cardiovascular therapies to support market growth 225 17.3.6 ITALY 230 17.3.6.1 Rising prevalence of cardiovascular risk factors to drive demand for interventional cardiology devices 230 17.3.7 SPAIN 234 17.3.7.1 Aging population and increasing cardiovascular disease burden to support market growth 234 17.3.8 REST OF EUROPE 238 17.4 ASIA PACIFIC 242 17.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 242 17.4.2 ASIA PACIFIC: VOLUME ANALYSIS OF INTERVENTIONAL CARDIOLOGY DEVICES, BY TYPE, 2024–2031 (THOUSAND UNITS) 243 17.4.3 CHINA 248 17.4.3.1 High tobacco consumption and rising cardiovascular disease burden driving market growth 248 17.4.4 JAPAN 252 17.4.4.1 Aging population and growing demand for minimally invasive cardiac procedures to drive market growth 252 17.4.5 INDIA 256 17.4.5.1 Rising cardiovascular disease burden and expanding healthcare access to drive market growth 256 17.4.6 AUSTRALIA 260 17.4.6.1 Rising prevalence of lifestyle-related cardiovascular diseases to drive market growth 260 17.4.7 SOUTH KOREA 264 17.4.7.1 Advancements in medical technology and cardiovascular care to support market growth 264 17.4.8 REST OF ASIA PACIFIC 268 17.5 LATIN AMERICA 272 17.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 273 17.5.2 LATIN AMERICA: VOLUME ANALYSIS OF INTERVENTIONAL CARDIOLOGY DEVICES, BY TYPE, 2024–2031 (THOUSAND UNITS) 273 17.5.3 BRAZIL 278 17.5.3.1 Rising cardiovascular disease burden and healthcare infrastructure investments to drive market growth 278 17.5.4 MEXICO 282 17.5.4.1 Rising diabetes and cardiovascular disease burden to drive market growth 282 17.5.5 REST OF LATIN AMERICA 286 17.6 MIDDLE EAST & AFRICA 290 17.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 290 17.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF INTERVENTIONAL CARDIOLOGY DEVICES, BY TYPE, 2024–2031 (THOUSAND UNITS) 291 17.6.3 GCC COUNTRIES 296 17.6.3.1 Rising diabetes and cardiovascular disease burden to drive market growth 296 17.6.4 KINGDOM OF SAUDI ARABIA (KSA) 300 17.6.4.1 Expanding cardiovascular care infrastructure and healthcare investments to support market growth in Saudi Arabia 300 17.6.5 UNITED ARAB EMIRATES (UAE) 304 17.6.5.1 Healthcare modernization and advanced cardiovascular care to support market growth in the UAE 304 17.6.6 OTHER GCC COUNTRIES 308 17.6.7 REST OF MIDDLE EAST & AFRICA 312 18 COMPETITIVE LANDSCAPE 317 18.1 OVERVIEW 317 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 317 18.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET 318 18.3 REVENUE ANALYSIS, 2023–2025 320 18.4 MARKET SHARE ANALYSIS, 2025 321 18.4.1 ANGIOPLASTY STENTS MARKET SHARE ANALYSIS, 2025 321 18.4.2 STRUCTURAL HEART DEVICES MARKET SHARE ANALYSIS, 2025 322 18.4.3 CATHETERS MARKET SHARE ANALYSIS, 2025 323 18.4.4 ANGIOPLASTY BALLOONS MARKET SHARE ANALYSIS, 2025 324 18.4.5 PLAQUE MODIFICATION DEVICES MARKET SHARE ANALYSIS, 2025 325 18.4.6 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET SHARE ANALYSIS, 2025 326 18.4.7 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET SHARE ANALYSIS, 2025 327 18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 329 18.5.1 STARS 329 18.5.2 EMERGING LEADERS 329 18.5.3 PERVASIVE PLAYERS 329 18.5.4 PARTICIPANTS 329 18.6 COMPANY FOOTPRINT 331 18.6.1 COMPANY FOOTPRINT: KEY PLAYERS, 2025 331 18.6.1.1 Company footprint 331 18.6.1.2 Region footprint 333 18.6.1.3 Product footprint 334 18.6.1.4 Angioplasty stents footprint 335 18.6.1.5 Structural heart devices footprint 336 18.6.1.6 Catheters footprint 337 18.6.1.7 Angioplasty balloons footprint 338 18.6.1.8 Plaque modification devices footprint 339 18.6.1.9 Hemodynamic flow alteration devices footprint 340 18.6.1.10 Other interventional cardiology devices footprint 341 18.6.1.11 End-user footprint 342   18.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 342 18.7.1 PROGRESSIVE COMPANIES 343 18.7.2 RESPONSIVE COMPANIES 343 18.7.3 DYNAMIC COMPANIES 343 18.7.4 STARTING BLOCKS 343 18.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 345 18.8 COMPANY VALUATION & FINANCIAL METRICS 347 18.8.1 FINANCIAL METRICS 347 18.8.2 COMPANY VALUATION 347 18.9 BRAND/PRODUCT COMPARATIVE ANALYSIS 348 18.10 COMPETITIVE SCENARIO 349 18.10.1 PRODUCT LAUNCHES & APPROVALS 349 18.10.2 DEALS 350 18.10.3 EXPANSIONS 351 19 COMPANY PROFILES 352 19.1 KEY PLAYERS 352 19.1.1 EDWARDS LIFESCIENCES CORPORATION 352 19.1.1.1 Business overview 352 19.1.1.2 Products offered 353 19.1.1.3 Recent developments 354 19.1.1.3.1 Product launches & approvals 354 19.1.1.3.2 Deals 355 19.1.1.4 MnM View 356 19.1.1.4.1 Key Strengths 356 19.1.1.4.2 Strategic Choices 356 19.1.1.4.3 Weaknesses & Competitive Threats 356 19.1.2 ABBOTT 357 19.1.2.1 Business overview 357 19.1.2.2 Products offered 358 19.1.2.3 Recent developments 361 19.1.2.3.1 Product launches & approvals 361 19.1.2.3.2 Deals 362 19.1.2.4 MnM view 362 19.1.2.4.1 Key strengths 362 19.1.2.4.2 Strategic choices 363 19.1.2.4.3 Weaknesses & competitive threats 363 19.1.3 MEDTRONIC 364 19.1.3.1 Business overview 364 19.1.3.2 Products offered 365 19.1.3.3 Recent developments 368 19.1.3.3.1 Product launches & approvals 368 19.1.3.3.2 Deals 369 19.1.3.4 MnM view 369 19.1.3.4.1 Key strengths 369 19.1.3.4.2 Strategic choices 369 19.1.3.4.3 Weaknesses & competitive threats 370 19.1.4 BOSTON SCIENTIFIC CORPORATION 371 19.1.4.1 Business overview 371 19.1.4.2 Products offered 372 19.1.4.3 Recent developments 377 19.1.4.3.1 Product launches & approvals 377 19.1.4.3.2 Deals 378 19.1.4.4 MnM view 378 19.1.4.4.1 Key strengths 378 19.1.4.4.2 Strategic choices 378 19.1.4.4.3 Weaknesses & competitive threats 379 19.1.5 TERUMO CORPORATION 380 19.1.5.1 Business overview 380 19.1.5.2 Products offered 381 19.1.5.3 Recent developments 385 19.1.5.3.1 Product launches 385 19.1.5.3.2 Deals 386 19.1.5.3.3 Expansions 386 19.1.5.3.4 Others 387 19.1.5.4 MnM view 387 19.1.5.4.1 Key strengths 387 19.1.5.4.2 Strategic choices 387 19.1.5.4.3 Weaknesses & competitive threats 387 19.1.6 KONINKLIJKE PHILIPS N.V. 388 19.1.6.1 Business overview 388 19.1.6.2 Products offered 389 19.1.6.3 Recent developments 390 19.1.6.3.1 Product launches & approvals 390 19.1.6.3.2 Deals 391 19.1.6.4 MnM view 391 19.1.6.4.1 Key strengths 391 19.1.6.4.2 Strategic choices 392 19.1.6.4.3 Weaknesses & competitive threats 392 19.1.7 CORDIS 393 19.1.7.1 Business overview 393 19.1.7.2 Products offered 393 19.1.7.3 Recent developments 395 19.1.7.3.1 Product launches & approvals 395 19.1.7.3.2 Deals 395 19.1.8 TELEFLEX INCORPORATED 396 19.1.8.1 Business overview 396 19.1.8.2 Products offered 397 19.1.8.3 Recent developments 401 19.1.8.3.1 Product approvals 401 19.1.8.3.2 Deals 402 19.1.9 ASAHI INTECC CO., LTD. 403 19.1.9.1 Business overview 403 19.1.9.2 Products offered 404 19.1.9.3 Recent developments 407 19.1.9.3.1 Deals 407 19.1.9.3.2 Expansions 408 19.1.10 COOK 409 19.1.10.1 Business overview 409 19.1.10.2 Products offered 409 19.1.10.3 Recent developments 411 19.1.10.3.1 Deals 411 19.1.11 B. BRAUN SE 412 19.1.11.1 Business overview 412 19.1.11.2 Products offered 413 19.1.11.3 Recent developments 417 19.1.11.3.1 Product launches & approvals 417 19.1.11.3.2 Deals 417 19.1.12 INTEGER HOLDINGS CORPORATION 418 19.1.12.1 Business overview 418 19.1.12.2 Products offered 419 19.1.12.3 Recent developments 420 19.1.12.3.1 Deals 420 19.1.12.3.2 Expansions 421 19.1.13 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD. 422 19.1.13.1 Business overview 422 19.1.13.2 Products offered 423 19.1.14 IVASCULAR S.L.U. 426 19.1.14.1 Business overview 426 19.1.14.2 Products offered 426 19.1.15 BIOSENSORS INTERNATIONAL GROUP, LTD. 428 19.1.15.1 Business overview 428 19.1.15.2 Products offered 428   19.2 OTHER PLAYERS 430 19.2.1 ENDOCOR GMBH & CO. KG 430 19.2.2 INSITU TECHNOLOGIES, INC. 431 19.2.3 MERIL LIFE SCIENCES PVT. LTD 432 19.2.4 ALVIMEDICA 433 19.2.5 CARDIONOVUM GMBH 434 19.2.6 MEDINOL 434 19.2.7 BALTON SP. 435 19.2.8 TRANSLUMINA 436 19.2.9 SINO MEDICAL SCIENCES TECHNOLOGY INC. 437 19.2.10 SMT 438 20 RESEARCH METHODOLOGY 439 20.1 RESEARCH DATA 439 20.1.1 SECONDARY DATA 440 20.1.1.1 Key secondary sources 441 20.1.2 PRIMARY DATA 442 20.1.2.1 Primary sources 442 20.1.2.2 Key data from primary sources 443 20.1.2.3 Key industry insights 444 20.1.2.4 Breakdown of primaries 444 20.2 MARKET SIZE ESTIMATION 446 20.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH 448 20.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION 449 20.2.3 APPROACH 3: TOP-DOWN APPROACH 450 20.2.4 APPROACH 4: BOTTOM-UP APPROACH 450 20.2.5 APPROACH 4: PRIMARY INTERVIEWS 451 20.2.6 APPROACH 5: DEMAND-SIDE APPROACH 451 20.2.7 APPROACH 6: VOLUME DATA ANALYSIS 452 20.3 DATA TRIANGULATION AND MARKET BREAKDOWN 455 20.4 MARKET SHARE ASSESSMENT 456 20.5 RESEARCH ASSUMPTIONS 456 20.5.1 STUDY ASSUMPTIONS 456 20.5.2 GROWTH RATE ASSUMPTIONS 456 20.6 RISK ASSESSMENT 457 20.6.1 RESEARCH LIMITATIONS 457   21 APPENDIX 458 21.1 DISCUSSION GUIDE 458 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 464 21.3 CUSTOMIZATION OPTIONS 466 21.4 RELATED REPORTS 466 21.5 AUTHOR DETAILS 467
圖表清單 List of Tables & Figures
TABLE 1 INCLUSIONS & EXCLUSIONS 38 TABLE 2 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD) 39 TABLE 3 DIABETES POPULATION, BY REGION, 2024 VS. 2050 53 TABLE 4 FDA MEDICAL DEVICE USER FEE STRUCTURE (MDUFA VI – FY2025) 58 TABLE 5 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 62 TABLE 6 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION) 65 TABLE 7 LIST OF KEY INTERVENTIONAL CARDIOLOGY DEVICE MANUFACTURERS 71 TABLE 8 LIST OF KEY END USERS 72 TABLE 9 LIST OF KEY REGULATORY BODIES 72 TABLE 10 AVERAGE SELLING PRICE TREND OF ANGIOPLASTY STENTS, BY TYPE, 2023–2025 (USD) 73 TABLE 11 AVERAGE SELLING PRICE OF DRUG-ELUTING STENTS, BY KEY PLAYER, 2025 (USD) 74 TABLE 12 AVERAGE SELLING PRICE TREND OF CATHETERS, BY TYPE, 2023–2025 (USD) 75 TABLE 13 AVERAGE SELLING PRICE TREND OF INTERVENTIONAL CARDIOLOGY DEVICES, BY REGION, 2023–2025 (USD) 76 TABLE 14 IMPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 78 TABLE 15 EXPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 78 TABLE 16 IMPORT DATA FOR HS CODE 9021-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 79 TABLE 17 EXPORT DATA FOR HS CODE 9021-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 80 TABLE 18 KEY BILLING CODES USED FOR INTERVENTIONAL CARDIOLOGY DEVICE CATEGORIES 81 TABLE 19 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: MAJOR CONFERENCES & EVENTS, 2026–2027 82 TABLE 20 EDWARDS SAPIEN 3 ULTRA RESILIA VALVE: SEVERE AORTIC STENOSIS PATIENT 84 TABLE 21 ABBOTT MITRACLIP: SEVERE RHEUMATIC MITRAL REGURGITATION 85 TABLE 22 BOSTON SCIENTIFIC WATCHMAN FLX: STROKE PREVENTION IN HIGH BLEEDING-RISK AF PATIENT 85 TABLE 23 RECIPROCAL TARIFF RATES ADJUSTED BY US, 2025 86 TABLE 24 KEY PRODUCT-RELATED TARIFF 87 TABLE 25 NORTH AMERICA: IMPACT OF US TARIFFS ON CANADA 88 TABLE 26 ASIA PACIFIC: IMPACT OF US TARIFFS ON CHINA, JAPAN, AND INDIA 88 TABLE 27 EUROPE: IMPACT OF US TARIFFS ON GERMANY AND UK 89 TABLE 28 LATIN AMERICA: IMPACT OF US TARIFFS ON MEXICO 89 TABLE 29 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: KEY PATENTS, 2023–2025 95 TABLE 30 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 31 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 TABLE 32 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 33 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 34 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106 TABLE 35 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INTERVENTIONAL CARDIOLOGY DEVICES 110 TABLE 36 KEY BUYING CRITERIA FOR INTERVENTIONAL CARDIOLOGY DEVICES, BY END USER 111 TABLE 37 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: ADOPTION BARRIERS & INTERNAL CHALLENGES 112 TABLE 38 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 112 TABLE 39 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: KEY PROFITABILITY DRIVERS 114 TABLE 40 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 116 TABLE 41 ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 117 TABLE 42 ANGIOPLASTY STENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 43 KEY PLAYERS PROVIDING DRUG-ELUTING STENTS 118 TABLE 44 DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 45 DRUG-ELUTING STENTS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 120 TABLE 46 KEY PLAYERS PROVIDING BARE-METAL STENTS 121 TABLE 47 BARE-METAL STENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 48 BARE METAL STENTS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 122 TABLE 49 KEY PLAYERS PROVIDING BIOABSORBABLE STENTS 123 TABLE 50 BIOABSORBABLE STENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 51 BIOABSORBABLE STENTS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 124 TABLE 52 STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 126 TABLE 53 STRUCTURAL HEART DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 54 KEY PLAYERS PROVIDING AORTIC VALVE THERAPY DEVICES 128 TABLE 55 AORTIC VALVE THERAPY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 56 AORTIC VALVE THERAPY DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 130 TABLE 57 KEY PLAYERS PROVIDING OTHER THERAPY DEVICES 130 TABLE 58 OTHER THERAPY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 59 OTHER THERAPY DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 132 TABLE 60 CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 134 TABLE 61 CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 62 KEY PLAYERS PROVIDING ANGIOGRAPHY CATHETERS 136 TABLE 63 ANGIOGRAPHY CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 64 ANGIOGRAPHY CATHETERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 138 TABLE 65 KEY PLAYERS PROVIDING GUIDING CATHETERS 139 TABLE 66 GUIDING CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 67 GUIDING CATHETERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 140 TABLE 68 KEY PLAYERS PROVIDING IVUS/OCT CATHETERS 141 TABLE 69 IVUS/OCT CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 70 IVUS/OCT CATHETERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 142 TABLE 71 ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 144 TABLE 72 ANGIOPLASTY BALLOONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 73 KEY PLAYERS PROVIDING OLD/NORMAL BALLOONS 146 TABLE 74 OLD/NORMAL ANGIOPLASTY BALLOONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 75 OLD/NORMAL BALLOONS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 148 TABLE 76 KEY PLAYERS PROVIDING DRUG-ELUTING BALLOONS 149 TABLE 77 DRUG-ELUTING BALLOONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 78 DRUG-ELUTING BALLOONS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 150 TABLE 79 KEY PLAYERS PROVIDING CUTTING/SCORING BALLOONS 151 TABLE 80 CUTTING/SCORING BALLOONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 81 CUTTING/SCORING BALLOONS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 152 TABLE 82 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 154 TABLE 83 PLAQUE MODIFICATION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 84 KEY PLAYERS PROVIDING THROMBECTOMY DEVICES 156 TABLE 85 THROMBECTOMY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 86 THROMBECTOMY DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 158 TABLE 87 KEY PLAYERS PROVIDING ATHERECTOMY DEVICES 159 TABLE 88 ATHERECTOMY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 89 ATHERECTOMY DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 160 TABLE 90 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 162 TABLE 91 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 92 KEY PLAYERS PROVIDING EMBOLIC PROTECTION DEVICES 164 TABLE 93 EMBOLIC PROTECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 94 EMBOLIC PROTECTION DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 166 TABLE 95 KEY PLAYERS PROVIDING CHRONIC TOTAL OCCLUSION DEVICES 167 TABLE 96 CHRONIC TOTAL OCCLUSION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 97 CHRONIC TOTAL OCCLUSION DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 168 TABLE 98 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 170 TABLE 99 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 100 KEY PLAYERS PROVIDING GUIDEWIRES 172 TABLE 101 GUIDEWIRES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 102 GUIDEWIRES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 174 TABLE 103 KEY PLAYERS PROVIDING VASCULAR CLOSURE DEVICES 175 TABLE 104 VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 105 VASCULAR CLOSURE DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 177 TABLE 106 KEY PLAYERS PROVIDING INTRODUCER SHEATHS 178 TABLE 107 INTRODUCER SHEATHS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 108 INTRODUCER SHEATHS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 179 TABLE 109 KEY PLAYERS PROVIDING BALLOON INFLATION DEVICES 180 TABLE 110 BALLOON INFLATION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 111 BALLOON INFLATION DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 181 TABLE 112 KEY PLAYERS PROVIDING HEMOSTASIS HEART VALVES 181 TABLE 113 HEMOSTASIS HEART VALVES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 114 HEMOSTASIS HEART VALVES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 183 TABLE 115 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 185 TABLE 116 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 117 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 118 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR STANDALONE HOSPITAL FACILITIES, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 119 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR LARGE CHAIN HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 120 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 121 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR CARDIAC CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 122 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 123 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 195 TABLE 124 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 198 TABLE 125 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 126 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 199 TABLE 127 NORTH AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 128 NORTH AMERICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 129 NORTH AMERICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 130 NORTH AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 131 NORTH AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 132 NORTH AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 133 NORTH AMERICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 134 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 202 TABLE 135 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 136 US: MACROECONOMIC INDICATORS 203 TABLE 137 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 203 TABLE 138 US: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 139 US: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 140 US: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 141 US: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 205 TABLE 142 US: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 205 TABLE 143 US: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 205 TABLE 144 US: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 145 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 206 TABLE 146 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 147 CANADA: MACROECONOMIC INDICATORS 207 TABLE 148 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 208 TABLE 149 CANADA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 150 CANADA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 151 CANADA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 152 CANADA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 153 CANADA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 154 CANADA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 210 TABLE 155 CANADA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 210 TABLE 156 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 210 TABLE 157 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 158 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 212 TABLE 159 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 160 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 213 TABLE 161 EUROPE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 162 EUROPE: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 163 EUROPE: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 164 EUROPE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 165 EUROPE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 166 EUROPE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 167 EUROPE: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 168 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 216 TABLE 169 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 170 GERMANY: MACROECONOMIC INDICATORS 217 TABLE 171 GERMANY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 218 TABLE 172 GERMANY: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 173 GERMANY: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 174 GERMANY: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 175 GERMANY: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 176 GERMANY: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 177 GERMANY: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 178 GERMANY: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 179 GERMANY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 220 TABLE 180 GERMANY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 181 FRANCE: MACROECONOMIC INDICATORS 222 TABLE 182 FRANCE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 222 TABLE 183 FRANCE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 184 FRANCE: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 223 TABLE 185 FRANCE: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 223 TABLE 186 FRANCE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 223 TABLE 187 FRANCE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 188 FRANCE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 189 FRANCE: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 190 FRANCE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 225 TABLE 191 FRANCE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 192 UK: MACROECONOMIC INDICATORS 226 TABLE 193 UK: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 226 TABLE 194 UK: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 227 TABLE 195 UK: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 227 TABLE 196 UK: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 227 TABLE 197 UK: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 198 UK: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 199 UK: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 200 UK: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 201 UK: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 229 TABLE 202 UK: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 203 ITALY: MACROECONOMIC INDICATORS 230 TABLE 204 ITALY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 231 TABLE 205 ITALY: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 206 ITALY: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 207 ITALY: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 208 ITALY: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 209 ITALY: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 210 ITALY: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 211 ITALY: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 212 ITALY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 233 TABLE 213 ITALY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 214 SPAIN: MACROECONOMIC INDICATORS 234 TABLE 215 SPAIN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 235 TABLE 216 SPAIN: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 217 SPAIN: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 218 SPAIN: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 219 SPAIN: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 220 SPAIN: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 221 SPAIN: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 222 SPAIN: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 223 SPAIN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 237 TABLE 224 SPAIN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 225 REST OF EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 238 TABLE 226 REST OF EUROPE; ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 227 REST OF EUROPE: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 228 REST OF EUROPE: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 229 REST OF EUROPE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 230 REST OF EUROPE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 231 REST OF EUROPE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 232 REST OF EUROPE: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 233 REST OF EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 241 TABLE 234 REST OF EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 235 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 243 TABLE 236 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 237 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 245 TABLE 238 ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 239 ASIA PACIFIC: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 240 ASIA PACIFIC: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 241 ASIA PACIFIC: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 242 ASIA PACIFIC: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 243 ASIA PACIFIC: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 244 ASIA PACIFIC: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 245 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 247 TABLE 246 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 247 CHINA: MACROECONOMIC INDICATORS 248 TABLE 248 CHINA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 249 TABLE 249 CHINA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 250 CHINA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 251 CHINA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 252 CHINA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 253 CHINA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 254 CHINA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 255 CHINA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 256 CHINA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 251 TABLE 257 CHINA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 258 JAPAN: MACROECONOMIC INDICATORS 252 TABLE 259 JAPAN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 253 TABLE 260 JAPAN: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 261 JAPAN: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 262 JAPAN CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 263 JAPAN: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 264 JAPAN: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 265 JAPAN: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 266 JAPAN: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 267 JAPAN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 255 TABLE 268 JAPAN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 269 INDIA: MACROECONOMIC INDICATORS 256 TABLE 270 INDIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 257 TABLE 271 INDIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 272 INDIA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 273 INDIA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 274 INDIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 275 INDIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 276 INDIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 277 INDIA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 278 INDIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 259 TABLE 279 INDIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 280 AUSTRALIA: MACROECONOMIC INDICATORS 260 TABLE 281 AUSTRALIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 261 TABLE 282 AUSTRALIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 283 AUSTRALIA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 284 AUSTRALIA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 285 AUSTRALIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 286 AUSTRALIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 287 AUSTRALIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 288 AUSTRALIA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 289 AUSTRALIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 263 TABLE 290 AUSTRALIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 264 TABLE 291 SOUTH KOREA: MACROECONOMIC INDICATORS 264 TABLE 292 SOUTH KOREA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 265 TABLE 293 SOUTH KOREA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 294 SOUTH KOREA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 295 SOUTH KOREA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 296 SOUTH KOREA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 297 SOUTH KOREA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 298 SOUTH KOREA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 299 SOUTH KOREA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 300 SOUTH KOREA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 267 TABLE 301 SOUTH KOREA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 302 REST OF ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 269 TABLE 303 REST OF ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 304 REST OF ASIA PACIFIC: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 305 REST OF ASIA PACIFIC: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 306 REST OF ASIA PACIFIC: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 307 REST OF ASIA PACIFIC: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 308 REST OF ASIA PACIFIC: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 309 REST OF ASIA PACIFIC: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 310 REST OF ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 272 TABLE 311 REST OF ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 312 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 273 TABLE 313 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 274 TABLE 314 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 274 TABLE 315 LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 316 LATIN AMERICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 317 LATIN AMERICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 318 LATIN AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 319 LATIN AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 320 LATIN AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 321 LATIN AMERICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 322 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 277 TABLE 323 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 324 BRAZIL: MACROECONOMIC INDICATORS 278 TABLE 325 BRAZIL: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 279 TABLE 326 BRAZIL: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 327 BRAZIL: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 328 BRAZIL: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 329 BRAZIL: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 330 BRAZIL: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 331 BRAZIL: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 332 BRAZIL: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 333 BRAZIL: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 281 TABLE 334 BRAZIL: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 335 MEXICO: MACROECONOMIC INDICATORS 282 TABLE 336 MEXICO: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 283 TABLE 337 MEXICO: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 338 MEXICO: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 339 MEXICO: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 340 MEXICO: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 341 MEXICO: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 342 MEXICO: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 343 MEXICO: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 344 MEXICO: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 285 TABLE 345 MEXICO: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 346 REST OF LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 286 TABLE 347 REST OF LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 348 REST OF LATIN AMERICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 349 REST OF LATIN AMERICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 350 REST OF LATIN AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 351 REST OF LATIN AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 352 REST OF LATIN AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 353 REST OF LATIN AMERICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 354 REST OF LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 289 TABLE 355 REST OF LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 356 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 291 TABLE 357 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 292 TABLE 358 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 292 TABLE 359 MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 360 MIDDLE EAST & AFRICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 361 MIDDLE EAST & AFRICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 362 MIDDLE EAST & AFRICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 363 MIDDLE EAST & AFRICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 364 MIDDLE EAST & AFRICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 365 MIDDLE EAST & AFRICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 366 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 295 TABLE 367 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 368 GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 296 TABLE 369 GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 297 TABLE 370 GCC COUNTRIES: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 371 GCC COUNTRIES: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 372 GCC COUNTRIES: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 373 GCC COUNTRIES: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 374 GCC COUNTRIES: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 375 GCC COUNTRIES: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 376 GCC COUNTRIES: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 377 GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 299 TABLE 378 GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 379 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 300 TABLE 380 KINGDOM OF SAUDI ARABIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 301 TABLE 381 KINGDOM OF SAUDI ARABIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 382 KINGDOM OF SAUDI ARABIA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 383 KINGDOM OF SAUDI ARABIA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 384 KINGDOM OF SAUDI ARABIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 385 KINGDOM OF SAUDI ARABIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 386 KINGDOM OF SAUDI ARABIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 387 KINGDOM OF SAUDI ARABIA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 388 KINGDOM OF SAUDI ARABIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 304 TABLE 389 KINGDOM OF SAUDI ARABIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 390 UNITED ARAB EMIRATES: KEY MACROINDICATORS 305 TABLE 391 UNITED ARAB EMIRATES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 305 TABLE 392 UNITED ARAB EMIRATES: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 393 UNITED ARAB EMIRATES: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 394 UNITED ARAB EMIRATES: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 395 UNITED ARAB EMIRATES: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 396 UNITED ARAB EMIRATES: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 397 UNITED ARAB EMIRATES: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 398 UNITED ARAB EMIRATES: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 399 UNITED ARAB EMIRATES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 308 TABLE 400 UNITED ARAB EMIRATES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 401 OTHER GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 309 TABLE 402 OTHER GCC COUNTRIES: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 403 OTHER GCC COUNTRIES: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 404 OTHER GCC COUNTRIES: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 405 OTHER GCC COUNTRIES: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 406 OTHER GCC COUNTRIES: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 407 OTHER GCC COUNTRIES: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 408 OTHER GCC COUNTRIES: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 409 OTHER GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 312 TABLE 410 OTHER GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 411 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 313 TABLE 412 REST OF MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 413 REST OF MIDDLE EAST & AFRICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 414 REST OF MIDDLE EAST & AFRICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 415 REST OF MIDDLE EAST & AFRICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 416 REST OF MIDDLE EAST & AFRICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 417 REST OF MIDDLE EAST & AFRICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 418 REST OF MIDDLE EAST & AFRICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 419 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 315 TABLE 420 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY HOSPITALS, 2024–2031 (USD MILLION) 316 TABLE 421 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES, JANUARY 2023–MAY 2026 318 TABLE 422 ANGIOPLASTY STENTS MARKET: DEGREE OF COMPETITION 321 TABLE 423 STRUCTURAL HEART DEVICES MARKET: DEGREE OF COMPETITION 322 TABLE 424 CATHETERS MARKET: DEGREE OF COMPETITION 323 TABLE 425 ANGIOPLASTY BALLOONS MARKET: DEGREE OF COMPETITION 324 TABLE 426 PLAQUE MODIFICATION DEVICES MARKET: DEGREE OF COMPETITION 325 TABLE 427 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET: DEGREE OF COMPETITION 326 TABLE 428 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DEGREE OF COMPETITION 327 TABLE 429 REGION FOOTPRINT 333 TABLE 430 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PRODUCT FOOTPRINT 334 TABLE 431 ANGIOPLASTY STENTS FOOTPRINT 335 TABLE 432 STRUCTURAL HEART DEVICES FOOTPRINT 336 TABLE 433 CATHETERS FOOTPRINT 337 TABLE 434 ANGIOPLASTY BALLOONS FOOTPRINT 338 TABLE 435 PLAQUE MODIFICATION DEVICES FOOTPRINT 339 TABLE 436 HEMODYNAMIC FLOW ALTERATION DEVICES FOOTPRINT 340 TABLE 437 OTHER INTERVENTIONAL CARDIOLOGY DEVICES FOOTPRINT 341 TABLE 438 END-USER FOOTPRINT 342 TABLE 439 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DETAILED LIST OF KEY START-UPS/SMES 345 TABLE 440 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 346 TABLE 441 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 349 TABLE 442 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DEALS, JANUARY 2023– MAY 2026 350 TABLE 443 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: EXPANSIONS, JANUARY 2023–MAY 2026 351 TABLE 444 EDWARDS LIFESCIENCES CORPORATION: COMPANY OVERVIEW 352 TABLE 445 EDWARDS LIFESCIENCES CORPORATION: PRODUCTS OFFERED 353 TABLE 446 EDWARDS LIFESCIENCES CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 354 TABLE 447 EDWARDS LIFESCIENCES CORPORATION: DEALS, JANUARY 2023–MAY 2026 355 TABLE 448 ABBOTT: COMPANY OVERVIEW 357 TABLE 449 ABBOTT: PRODUCTS OFFERED 358 TABLE 450 ABBOTT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 361 TABLE 451 ABBOTT: DEALS, JANUARY 2023–MAY 2026 362 TABLE 452 MEDTRONIC: COMPANY OVERVIEW 364 TABLE 453 MEDTRONIC: PRODUCTS OFFERED 365 TABLE 454 MEDTRONIC: PRODUCT APPROVALS, JANUARY 2023–MAY 2026 368 TABLE 455 MEDTRONIC: DEALS, JANUARY 2023–MAY 2026 369 TABLE 456 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 371 TABLE 457 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 372 TABLE 458 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 377 TABLE 459 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2023–MAY 2026 378 TABLE 460 TERUMO CORPORATION: COMPANY OVERVIEW 380 TABLE 461 TERUMO CORPORATION: PRODUCTS OFFERED 381 TABLE 462 TERUMO CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 385 TABLE 463 TERUMO CORPORATION: DEALS, JANUARY 2023–MAY 2026 386 TABLE 464 TERUMO CORPORATION.: EXPANSIONS, JANUARY 2023–MAY 2026 386 TABLE 465 TERUMO CORPORATION.: EXPANSIONS, JANUARY 2023–MAY 2026 387 TABLE 466 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 388 TABLE 467 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 389 TABLE 468 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 390 TABLE 469 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2023–MAY 2026 391 TABLE 470 CORDIS: COMPANY OVERVIEW 393 TABLE 471 CORDIS.: PRODUCTS OFFERED 393 TABLE 472 CORDIS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 395 TABLE 473 CORDIS: DEALS, JANUARY 2023–MAY 2026 395 TABLE 474 TELEFLEX INCORPORATED: COMPANY OVERVIEW 396 TABLE 475 TELEFLEX INCORPORATED: PRODUCTS OFFERED 397 TABLE 476 TELEFLEX INCORPORATED: PRODUCT APPROVALS, JANUARY 2023–MAY 2026 401 TABLE 477 TELEFLEX INCORPORATED.: DEALS, JANUARY 2023–MAY 2026 402 TABLE 478 ASAHI INTECC CO., LTD.: COMPANY OVERVIEW 403 TABLE 479 ASAHI INTECC CO., LTD.: PRODUCTS OFFERED 404 TABLE 480 ASAHI INTECC CO., LTD.: DEALS, JANUARY 2023–MAY 2026 407 TABLE 481 ASAHI INTECC CO., LTD: EXPANSIONS, JANUARY 2023–MAY 2026 408 TABLE 482 COOK: COMPANY OVERVIEW 409 TABLE 483 COOK: PRODUCTS OFFERED 409 TABLE 484 COOK: DEALS, JANUARY 2023–MAY 2026 411 TABLE 485 B. BRAUN SE: COMPANY OVERVIEW 412 TABLE 486 B. BRAUN SE: PRODUCTS OFFERED 413 TABLE 487 B. BRAUN SE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 417 TABLE 488 B. BRAUN SE: DEALS, JANUARY 2023–MAY 2026 417 TABLE 489 INTEGER HOLDINGS CORPORATION: COMPANY OVERVIEW 418 TABLE 490 INTEGER HOLDINGS CORPORATION: PRODUCTS OFFERED 419 TABLE 491 INTEGER HOLDINGS CORPORATION.: DEALS, JANUARY 2023–MAY 2026 420 TABLE 492 INTEGER HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2023–MAY 2026 421 TABLE 493 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: COMPANY OVERVIEW 422 TABLE 494 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD: PRODUCTS OFFERED 423 TABLE 495 IVASCULAR S.L.U.: COMPANY OVERVIEW 426 TABLE 496 IVASCULAR S.L.U: PRODUCTS OFFERED 426 TABLE 497 BIOSENSORS INTERNATIONAL GROUP, LTD.: COMPANY OVERVIEW 428 TABLE 498 BIOSENSORS INTERNATIONAL GROUP, LTD.: PRODUCTS OFFERED 428 TABLE 499 STUDY ASSUMPTIONS 456 TABLE 500 RISK ASSESSMENT ANALYSIS 457 FIGURE 1 INTERVENTIONAL CARDIOLOGY DEVICES MARKET SEGMENTATION & REGIONAL SCOPE 37 FIGURE 1 MARKET SCENARIO 41 FIGURE 2 GLOBAL INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2024–2031 42 FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2023–2025 43 FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF INTERVENTIONAL CARDIOLOGY DEVICES MARKET 43 FIGURE 5 HIGH-GROWTH SEGMENTS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2026–2031 44 FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 45 FIGURE 7 STRONG FUTURE FOR MINIMALLY INVASIVE AND ADVANCED CARDIOVASCULAR INTERVENTIONS TO BOOST MARKET GROWTH 47 FIGURE 8 HOSPITALS AND CHINA DOMINATED MARKET IN 2025 48 FIGURE 9 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 49 FIGURE 10 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50 FIGURE 11 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 63 FIGURE 12 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: SUPPLY CHAIN ANALYSIS 67 FIGURE 13 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: VALUE CHAIN ANALYSIS 69 FIGURE 14 INTERVENTIONAL CARDIOLOGY DEVICES MARKET ECOSYSTEM 70 FIGURE 15 AVERAGE SELLING PRICE TREND OF STRUCTURAL HEART DEVICES, BY TYPE, 2023–2025 (USD) 75 FIGURE 16 AVERAGE SELLING PRICE OF ANGIOPLASTY STENTS, BY REGION, 2025 (USD) 77 FIGURE 17 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83 FIGURE 18 INVESTMENT & FUNDING SCENARIO 84 FIGURE 19 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR INTERVENTIONAL CARDIOLOGY DEVICE PATENTS, JANUARY 2015–MAY 2026 94 FIGURE 20 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: AI USE CASES 100 FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INTERVENTIONAL CARDIOLOGY DEVICES 109 FIGURE 22 KEY BUYING CRITERIA FOR INTERVENTIONAL CARDIOLOGY DEVICES, BY END USER 110 FIGURE 23 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET SNAPSHOT 197 FIGURE 24 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET SNAPSHOT 243 FIGURE 25 REVENUE ANALYSIS OF KEY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2023−2025) 320 FIGURE 26 ANGIOPLASTY STENTS MARKET SHARE, BY KEY PLAYER, 2025 321 FIGURE 27 STRUCTURAL HEART DEVICES MARKET SHARE, BY KEY PLAYER, 2025 322 FIGURE 28 CATHETERS MARKET SHARE, BY KEY PLAYER, 2025 323 FIGURE 29 ANGIOPLASTY BALLOONS MARKET SHARE, BY KEY PLAYER, 2025 324 FIGURE 30 PLAQUE MODIFICATION DEVICES MARKET SHARE, BY KEY PLAYER, 2025 325 FIGURE 31 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET SHARE, BY KEY PLAYER, 2025 326 FIGURE 32 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET SHARE, BY KEY PLAYER, 2025 327 FIGURE 33 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 330 FIGURE 34 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPANY FOOTPRINT 331 FIGURE 35 INTERVENTIONAL CARDIOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 344 FIGURE 36 EV/EBITDA OF KEY VENDORS 347 FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 347 FIGURE 38 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 348 FIGURE 39 EDWARDS LIFESCIENCES CORPORATION: COMPANY SNAPSHOT (2025) 353 FIGURE 40 ABBOTT: COMPANY SNAPSHOT (2025) 358 FIGURE 41 MEDTRONIC: COMPANY SNAPSHOT (2025) 365 FIGURE 42 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2025) 372 FIGURE 43 TERUMO CORPORATION: COMPANY SNAPSHOT (2025) 381 FIGURE 44 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2025) 389 FIGURE 45 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2025) 397 FIGURE 46 ASAHI INTECC CO., LTD.: COMPANY SNAPSHOT (2025) 404 FIGURE 47 B. BRAUN SE: COMPANY SNAPSHOT (2025) 413 FIGURE 48 INTEGER HOLDINGS CORPORATION: COMPANY SNAPSHOT (2025) 419 FIGURE 49 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: COMPANY SNAPSHOT (2025) 423 FIGURE 50 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: RESEARCH DESIGN 439 FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 444 FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 445 FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 445 FIGURE 54 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 447 FIGURE 55 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 448 FIGURE 56 REVENUE SHARE ANALYSIS ILLUSTRATION: MEDTRONIC (2025) 449 FIGURE 57 TOP-DOWN APPROACH 450 FIGURE 58 BOTTOM-UP APPROACH 450 FIGURE 59 DEMAND-SIDE APPROACH 452 FIGURE 60 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2026–2031) 453 FIGURE 61 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 454 FIGURE 62 DATA TRIANGULATION METHODOLOGY 455

同分類最新報告(醫療器材)

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們